Paola Giordano

Prof. Dr. Paola Giordano

Dipartimento di Scienze biomediche e oncologia umana, Università degli Studi di Bari, Bari 70121, Italy

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 September 2013 in Blood
Verified
Journal Article
Closed access
PDF file
PNPatrizia Noris
Patrizia Noris
RFRemi Favier
Remi Favier
MAMarie-Christine Alessi
Marie-Christine Alessi
AGAmy E. Geddis
Amy E. Geddis
SKShinji Kunishima
Shinji Kunishima
CBCarlo L. Balduini
Carlo L. Balduini

25 April 2013 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
PNPatrizia Noris
Patrizia Noris
CKCatherine Marie Klersy
Catherine Marie Klersy
PGPaolo Gresele
Paolo Gresele
FGFiorina Giona
Fiorina Giona
Paola GiordanoPaola Giordano
Paola Giordano
TPThe Italian ‘gRuppo di Studio Delle Piastrine’
The Italian ‘gRuppo di Studio Delle Piastrine’
Summary: The most frequent forms of inherited thrombocytopenia (IT) are characterized by platelet size abnormalities and it has been suggested that this parameter is useful for their differentiation from immune thrombocytopenia (ITP). Recently, a monocentric study identified cut‐off values for mean platelet volume (MPV) and mean platelet diameter (MPD) with good diagnostic accuracy in this respect. To validate these cut‐off values in a different and larger case series of patients, we enrolled 130 subjects with ITP and 113 with IT in six different centres. The platelet count and MPV was each measured by the instrument routinely used in each institution. In some centres, platelet count was also measured by optical microscopy. MPD was evaluated centrally by image analysis of peripheral blood films. The previously identified cut‐off value for MPV had 91% specificity in distinguishing ITP from inherited macrothrombocytopenias (mono and biallelic Bernard‐Soulier, MYH9‐related disease), while its sensitivity was greatly variable depending on the instrument used. With an appropriate instrument, specificity was 83%. The diagnostic accuracy of MPD was lower than that obtained with MPV. We concluded that MPV is a useful parameter for differentiating ITP from IT provided that it is measured by appropriate cell counters.

14 May 2013 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
PDF file
VCValerio Cecinati
Valerio Cecinati
NPNicola Principi
Nicola Principi
LBLetizia Pomponia Brescia
Letizia Pomponia Brescia
Paola GiordanoPaola Giordano
Paola Giordano
Susanna EspositoSusanna Esposito
Susanna Esposito
The most important reasons cited by the opponents of vaccines are concerns about vaccine safety. Unlike issues such as autism for which no indisputable documentation of direct relationship with vaccine use is available, immune thrombocytopenic purpura (ITP) is an adverse event that can really follow vaccine administration, and may limit vaccine use because little is known about which vaccines it may follow, its real incidence and severity, the risk of chronic disease, or the possibility of recurrences after new doses of the same vaccine. The main aim of this review is to clarify the real importance of thrombocytopenia as an adverse event and discuss how it may interfere with recommended vaccination schedules. The available data clearly indicate that ITP is very rare and the only vaccine for which there is a demonstrated cause-effect relationship is the measles, mumps and rubella (MMR) vaccine that can occur in 1 to 3 children every 100,000 vaccine doses. However, also in this case, the incidence of ITP is significantly lower than that observed during the natural diseases that the vaccine prevents. Consequently, ITP cannot be considered a problem limiting vaccine use except in the case of children suffering from chronic ITP who have to receive MMR vaccine. In these subjects, the risk-benefit ratio of the vaccine should be weighed against the risk of measles in the community.

Maria Felicia FaienzaMaria Felicia Faienza
Maria Felicia Faienza
GLGiuseppe Lassandro
Giuseppe Lassandro
MCMariangela Chiarito
Mariangela Chiarito
FVFederica Valente
Federica Valente
LCLoredana Ciaccia
Loredana Ciaccia
Paola GiordanoPaola Giordano
Paola Giordano
Bone remodeling is a lifelong process, due to the balanced activity of the osteoblasts (OBs), the bone-forming cells, and osteoclasts (OCs), the bone-resorbing cells. This equilibrium is mainly regulated by the WNT-ß-cathenin pathway and the RANK-RANKL/OPG system, respectively. Bone ageing is a process which normally occurs during life due to the imbalance between bone formation and bone resorption, potentially leading to osteoporosis. Bone loss associated with bone ageing is determined by oxidative stress, the result of the increasing production of reactive oxygen species (ROS). The promotion of physical exercise during growth increases the chances of accruing bone and delaying the onset of osteoporosis. Several studies demonstrate that physical exercise is associated with higher bone mineral density and lower fracture incidence, and the resulting bone mineral gain is maintained with ageing, despite a reduction of physical activity in adulthood. The benefits of exercise are widely recognized, thus physical activity is considered the best non-pharmacologic treatment for pathologies such as osteoporosis, obesity, diabetes and cardiovascular disease. We reviewed the physiological mechanisms which control bone remodeling, the effects of physical activity on bone health, and studies on the impact of exercise in reducing bone ageing.

6 January 2011 in European Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
Paola GiordanoPaola Giordano
Paola Giordano
GVGiovanni Carlo Del Vecchio
Giovanni Carlo Del Vecchio
VCValerio Cecinati
Valerio Cecinati
Maurizio DelvecchioMaurizio Delvecchio
Maurizio Delvecchio
MAMaria Altomare
Maria Altomare
Maria Felicia FaienzaMaria Felicia Faienza
Maria Felicia Faienza

27 February 2013 in Hormone Research in Paediatrics
Verified
Journal Article
Closed access
PDF file
Maria Felicia FaienzaMaria Felicia Faienza
Maria Felicia Faienza
GBGiacomina Brunetti
Giacomina Brunetti
AVAnnamaria Ventura
Annamaria Ventura
MDMariangela D'ANiello
Mariangela D'ANiello
TPTiziana Pepe
Tiziana Pepe
LCLuciano Cavallo
Luciano Cavallo
Background/Aims: We studied the association of low birth weight with ultrasound-assessed nonalcoholic fatty liver disease (NAFLD) to test the hypothesis that fetal growth retardation followed by a rapid weight catch-up growth might be an additional factor responsible for liver steatosis via insulin resistance (IR) and/or intra-abdominal fat. Methods: We enrolled 23 children born small for gestational age (SGA) with a rapid catch-up growth within the first 6-12 months, and 24 appropriate for gestational age (AGA) children as controls. All children underwent anthropometric, body composition measurements and evaluation of liver function tests, lipid profile, plasma glucose and insulin levels. Abdominal ultrasonography was performed in order to asses liver steatosis and thickness of subcutaneous and visceral adipose tissue. Results: NAFLD were observed in 8 out of the 23 SGA children (34.8%). IR and visceral fat were significantly increased in children with hepatic steatosis compared to those without. IR index was significantly related to liver steatosis, independently of body mass index standard deviation score and visceral fat. Conclusions: NAFLD should be recognized as an emerging problem in SGA prepubertal children who presented a rapid weight gain in postnatal life, and IR plays the key role. An appropriate diet during pregnancy and in the first year of life might prevent metabolic syndrome and NAFLD in these subjects.